Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00168350 | Memantine in Patients With Chronic Glaucoma | PHASE3 | COMPLETED | 1,179 | — | — | Mar 1, 2000 | Sep 1, 2006 | Nov 4, 2010 | - | — |
| NCT00141882 | Memantine in Patients With Chronic Glaucoma | PHASE3 | COMPLETED | 1,119 | — | — | Mar 1, 1999 | Aug 1, 2006 | Nov 4, 2010 | - | — |
| Name | Type | Description |
|---|---|---|
| memantine | DRUG | - |
Inclusion Criteria: * glaucoma damage on examination of visual field and optic disc * good visual acuity (with glasses if needed)
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |